All In Biotech

Drug Trial Radar · NCT05027139

A Study of Zanidatamab (ZW25) With Evorpacept (ALX148) in Patients With Advanced HER2-expressing Cancer

A Phase 1b/2, 2-part Open-label Study to Assess the Safety and Antitumor Activity of Zanidatamab in Combination With ALX148 in Advanced HER2-expressing Cancer

Last checked: Nov 19, 2026Latest source record: Jul 1, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

52

Actual

Start

Sep 15, 2021

Primary completion

Aug 29, 2025

Study completion Sep 30, 2025

Sponsor

Lead sponsor
Jazz PharmaceuticalsJazz Pharmaceuticals (JAZZ)
Sponsor type
Industry
Collaborators
ALX Oncology Inc.
First posted
Aug 30, 2021

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is being done to find out if zanidatamab when given with evorpacept (ALX148) is safe and can treat patients with advanced (locally advanced \[inoperable\] and/or metastatic) human epidermal growth factor receptor 2 (HER2)-expressing cancer.

Conditions

  • HER2-expressing Cancers

Interventions

  • ZanidatamabDrug

    Administered intravenously (IV)

  • EvorpaceptDrug

    Administered IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of dose-limiting toxicities (DLTs; Part 1)Time frame: Up to 4 weeks
  2. Incidence of AEs (Part 1)Time frame: Up to 7 months
  3. Incidence of clinical laboratory abnormalities (Part 1)Time frame: Up to 7 months
  4. Confirmed objective response rate (ORR)(Part 2)Time frame: Up to 2 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • UC San Diego - Moores Cancer Center

    La Jolla, California

  • UCLA Department of Medicine Hematology/Oncology

    Los Angeles, California

  • UC Irvine Health - Chao Family Comprehensive Cancer Center

    Orange, California

  • Florida Cancer Specialists

    Sarasota, Florida

  • Astera Cancer Care

    East Brunswick, New Jersey

  • University Hospitals Cleveland Medical Center

    Cleveland, Ohio

  • Magee-Womens Hospital of UPMC

    Pittsburgh, Pennsylvania

  • The University of Texas MD Anderson Cancer Center

    Houston, Texas

  • University of Vermont Medical Center

    Burlington, Vermont

  • Northwest Medical Specialties, PLLC

    Tacoma, Washington

  • University of Wisconsin - Madison

    Madison, Wisconsin

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.